Top Markets
Coin of the day
Alpha Cognition Inc Alpha Cognition Inc

Alpha Cognition Inc

ACOG
Rang in Aktien #19830
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aktienkurs
$9.61
Marktkapitalisierung
$149.33M
Veränderung (1 Tag)
-1.39%
Veränderung (1 Jahr)
24.38%
Land
US
Handel Alpha Cognition Inc (ACOG)

Kategorie

Dividendenrendite-Verlauf für Alpha Cognition Inc (ACOG)
Dividendenrendite (TTM) von Alpha Cognition Inc (Aktienkürzel: ACOG) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Alpha Cognition Inc (ACOG) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH